TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cryoanesthesia for Intravitreal Injections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral macular disease due to either exudative macular degeneration or diabetic retinopathy requiring bilateral intravitreal injections~* Have had at least one prior intravitreal injection~* Able to give informed consent~Exclusion Criteria:~* Unilateral disease~* Unable to provide consent~* Preexisting conjunctival, episcleral or scleral defects or disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Cryoanesthesia Device -5 degrees Celsius for 10 seconds (Type: EXPERIMENTAL): All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device.
- Cryoanesthesia Device -5 degrees Celsius for 20 seconds (Type: EXPERIMENTAL): All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device.
- Cryoanesthesia Device -7 degrees Celsius for 20 seconds (Type: EXPERIMENTAL): All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device.
- Cryoanesthesia Device -10 degrees Celsius for 10 seconds (Type: EXPERIMENTAL): All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device.
- Cryoanesthesia Device -10 degrees Celsius for 20 seconds (Type: EXPERIMENTAL): All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device.
- Lidocaine (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will have their other eye receive anesthesia via the current standard of care treatment method (lidocaine) prior to receiving an intravitreal injection.~Lidocaine: Lidocaine will be applied to the non-cryoanesthesia eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40 - 84 years old, Aortic stenosis, Scheduled for Aortic valve replacement.~Exclusion Criteria:~* Poor quality echocardiographic images unsuitable for analysis~* Off -pump surgical procedure~* Anticipated deep hypothermic circulatory arrest~* Any contraindications to transesophageal echocardiogram (TEE) or other proposed intervention~* Unable to give written informed consent (non-English speaking, vulnerable patients, etc.)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- hyperinsulinemic normoglycemic clamp (HNC) (Type: EXPERIMENTAL): Patients will be randomized to receive treatment with HNC during cardiac surgery.
- standard glucose management (Type: PLACEBO_COMPARATOR): Patients will be randomized to receive treatment with standard glucose management during cardiac surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 45-65 women with amenorrhea for over 24 months.~* Clinical vaginal atrophy diagnosis.~Exclusion Criteria:~* BMI \> 35.~* Previous use of oral estrogen therapy in the last 6 months.~* History or current diagnosis of cancer.~* Altered cervical smear in the last 12 months.~* Renal or hepatic insufficiency.~* Drug-induced menopause.~* Previous use of steroids.~* Previous vaginal radiotherapy therapy.~* Vulvovaginitis.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CO2 laser & Estrogen (Type: EXPERIMENTAL): Effective fractional CO2 laser therapy and effective estrogen vaginal cream
- CO2 laser & Placebo of Estrogen (Type: ACTIVE_COMPARATOR): Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.
- Placebo of CO2 laser & Estrogen (Type: SHAM_COMPARATOR): Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of a solid malignancy that is refractory to standard therapy or for which no standard therapy exists.~* Patients has a good performance status (ECOG 0 or 1)~Exclusion Criteria:~* Prior treatment with either pemetrexed or SU011248.~* Coughing up blood within 4 weeks before starting study treatment (small amounts okey).~* Hypertension that cannot be controlled by medications.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDD (Type: EXPERIMENTAL): None
- 2/1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Diabetes After Gastric Bypass With Sitagliptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a resident of the NYC metropolitan area or be able to come for emergency unscheduled and regular weekly meetings in Manhattan.~* HbA1c ≥ 6.5% and ≤ 8.5 % or a fasting glucose ≥ 126 mg/dL or a random glucose ≥ 200 mg/dL at least 12 months after GBP surgery confirmed by central laboratory.~* Subject is capable and willing to give informed consent.~* Subject is otherwise in good general health, based on medical history and physical examination.~* Subject is a non smoker for at least 6 months prior to study start~* Female subjects of child bearing potential must use oral, injected or implanted hormonal methods of contraception from at least the commencement of their last normal period prior to the first administration of the challenge agent. Subjects using hormonal contraception should use a barrier method in addition from the first administration of challenge agent until their next normal period following the end of the study.~Exclusion Criteria:~* History of type 1 diabetes~* Female subject is pregnant or breastfeeding.~* Recent (\< 30 days) or simultaneous participation in another clinical trial.~* Any situation that can compromise the study, including serious illness or a predictable lack of cooperation from the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin phosphate (Type: ACTIVE_COMPARATOR): 100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 1 Placebo pill / day PO once a day for 4-5 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Active rheumatoid arthritis according to criteria of American College of Rheumatologists (2010), that was diagnosed at least 6 months prior to screening.~* Active rheumatoid arthritis at screening despite of therapy with methotrexate for 3 last months.~* Use of methotrexate in stable dose for at least 4 weeks before screening (10-25 mg per week).~* History of ineffective treatment with basic antiinflammatory drugs (including methotrexate).~Exclusion Criteria:~* Previous therapy of rheumatoid arthritis with monoclonal antibodies (including anti-tumor necrosis factor drugs)~* Felty's syndrome~* Functional status - class IV according to ACR classification (1991)~* Low activity of rheumatoid arthritis (DAS28-CRP(4) index less than 3.2)~* Patient needs corticosteroids in a dose more than 10 mg (recalculated to prednisolone) before signing informed consent.~* Patients needs equal of less than 10 mg prednisolone but the dose was not stable for last 4 weeks prior to infliximab treatment~* Prior use of disease-modifying antirheumatic drugs including methotrexate, sulfasalazin, chloroquine or hydroxychloroquine for up to 4 weeks before randomization.~* Prior use of alkylating agents for up to 12 months prior to signing informed consent.~* Intraarticular use of corticosteroids for up to 4 weeks before randomization.~* Prior use of live or attenuated vaccines for up to 8 weeks before signing informed consent.~* Diagnosis of tuberculosis.~* Body mass more than 130 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BCD-055 (Type: EXPERIMENTAL): Patients in this group will receive BCD-055 in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
- Remicade® (Type: ACTIVE_COMPARATOR): Patients in this group will receive Remicade® in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Organ Protection With Sevoflurane Postconditioning After Cardiac Surgery With Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* CABG and/or heart valve surgery with CPB~* Ejection fraction (EF) = 30%~* Canadian Cardiovascular Society (CCS) classification = 3~* Ages 18 to 90 years old~Exclusion criteria:~* Pulmonary disease: forced expiratory volume in one second (FEV1) \< 80%; FEV1/forced vital capacity (FVC) \< 70%~* Renal disease and/ or creatinine-clearance \< 60 ml/min~* Previous cardiac surgery~* Emergency procedures~* Postoperative intra aortic balloon pump (IABP) requirement~* Myocardial infarction \< 7d~* Steroid treatment~* Insulin-dependent diabetes~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: EXPERIMENTAL): None
- Propofol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a BMI of greater than or equal to ≥27 kg/m² and \<less than 35 kg/m² with at least 2 obesity-related health problems or ≥35 kg/m² with at least 1 obesity-related health problems. Health problems are IGT, hyperlipidemia, or NAFLD.~* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.~Exclusion Criteria:~* Have diabetes.~* Acute or chronic liver disease other than NAFLD.~* Have a self-reported change in body weight \>5 kg within 3 months prior to screening.~* Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months.~* Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2, calculated by Japanese Society of Nephrology coefficient-modified Chronic Kidney Disease-Epidemiology equation during screening.~* Have a known clinically significant gastric emptying abnormality.~* Have had a history of chronic or acute pancreatitis.~* Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 micro units per milliliter (μIU/mL) at screening.~* Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.~* Have a history of significant active or unstable major depressive disorder or other severe psychiatric disorder within the last 2 years.~* Have a cardiovascular condition within 3 months prior to randomization~* Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome type 2.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 Milligrams (mg) Tirzepatide (Type: EXPERIMENTAL): Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
- 15 mg Tirzepatide (Type: EXPERIMENTAL): Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo administered SC QW.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serologically confirmed HIV infection;~* Gestational age of 28 to 38 weeks;~* Previous selection of a NVP-based PMTCT regimen (with or without ZDV)~* Willingness to participate in a randomized trial;~* Willingness to follow up in a postpartum visit schedule;~* Willingness to allow her infant to participate in this trial;~Exclusion Criteria:~* Use of antiretroviral medications before this pregnancy, even in a single dose.~* Current use of antiretroviral medications for treatment of advanced HIV disease and/or AIDS~* Illness or complication of pregnancy likely to warrant transfer to the University Teaching Hospital (UTH), known at time of randomization;~* Known or suspected allergy to NVP or other benzodiazepine medications;~* History of known liver disease.~* Hemoglobin level of 7.9 g/dL or less

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- combination tenofovir-emtricitabine (Type: EXPERIMENTAL): None
- control arm (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MISOBEST - Orally Misoprostol Solution (Cytotec®) Versus Orally Misoprostol as a Tablet (Angusta®) for Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton gestations~* Cephalic presentation~* ≥37-42+0 weeks of gestation~* Unfavorable cervix score BS \<6 in nulliparous women and \<5 in parous women~* All participating women in the studies will receive oral and written information and must give informed consent before participation~Exclusion Criteria:~1. Inability to understand the study information written in Swedish or English~2. Previous hysterotomy (scar in the uterine myometrium)~3. Non-reassuring cardiotocography (CTG) on admission (the door-test, first 20 minutes of registration of CTG).~4. Hypersensitivity to the active substance~5. If active labor has started~6. When oxytocin infusion is already used~7. Placenta previa~8. Renal failure (GFR \<15 ml/min/1.73 m2).~9. Any condition or circumstance due to which the investigator considers it is not in the best interest of subject to participate in the study or the inclusion of a subject risks negatively impacting the scientific or ethical integrity of the clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cytotec® (Type: EXPERIMENTAL): IOL with misoprostol oral solution (Cytotec®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
- Angusta® (Type: ACTIVE_COMPARATOR): IOL with misoprostol oral tablets (Angusta®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Currently suffering from an acute exacerbation of schizophrenia. Caregiver required.~Exclusion Criteria:~* Have an uncontrolled, unstable medical condition. Have any other pyschiatric disorder other than schizophrenia as a primary diagnosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Asenapine 5 mg BID
- 2 (Type: EXPERIMENTAL): Asenapine 10 mg BID
- 3 (Type: ACTIVE_COMPARATOR): Haloperidol 4m mg BID
- 4 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib Ointment For Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline~* At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)~* If received certain treatments, should be off treatment for a minimum period of time (washout)~Exclusion Criteria:~* Currently have non-plaque forms of psoriasis or drug-induced psoriasis~* Require treatment with or cannot stop medication(s) prohibited during the study~* Have certain laboratory abnormalities at Baseline~* Current or history of certain infections~* Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group A (Type: EXPERIMENTAL): None
- Treatment Group B (Type: EXPERIMENTAL): None
- Treatment Group C (Type: PLACEBO_COMPARATOR): None
- Treatment Group D (Type: EXPERIMENTAL): None
- Treatment Group E (Type: EXPERIMENTAL): None
- Treatment Group F (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who had received at least one dose of the study vaccine in the primary study~* Written informed consent obtained from each subject before each blood sampling visit~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- Engerix 4D + HBIg Group (Type: EXPERIMENTAL): Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
- Engerix 3D + HBIg Group (Type: EXPERIMENTAL): Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
- Engerix 4D (Type: EXPERIMENTAL): Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, 6 and 60.
- Engerix 3D Group (Type: EXPERIMENTAL): Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, and 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete